[Staging and treatment response assessment with radiological and nuclear medicine approaches for non-Hodgkin...

Non-Hodgkin lymphomas (NHL) represent a heterogeneous group of malignant diseases in which the choice of imaging modality and response criteria strongly depends on histology and clinical context. Selecting the appropriate method is essential for individualized treatment planning.

According to the Lugano classification, ¹⁸F‑fluorodeoxyglucose positron emission tomography/computed tomography (¹⁸F‑FDG PET/CT) is the reference standard for staging and response assessment in ¹⁸F-FDG-avid NHL. For other lymphoma subtypes with low or variable ¹⁸F-FDG avidity, or in cases where reimbursement by statutory health insurance (GKV) is lacking, contrast-enhanced CT is typically used.

This article discusses the new classification systems Lymphoma Response to Immunomodulatory Therapy Criteria (LYRIC) and Response Evaluation Criteria in Lymphoma (RECIL), as well as specific features of certain lymphoma subtypes and novel imaging approaches such as whole-body MRI and innovative PET tracers.

This narrative review does not include a systematic evaluation of sensitivity or specificity data.

In ¹⁸F-FDG-avid lymphomas ¹⁸F‑FDG PET/CT remains the gold standard for precise staging and response assessment.

Imaging is essential for tailored therapy planning and monitoring in NHL. As most NHL subtypes are ¹⁸FDG-avid, PET/CT is the reference standard. However, contrast-enhanced CT continues to play a significant role, particularly in Germany. New PET tracers and whole-body MRI offer promising approaches but require further studies and standardization.